[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-429909-105":59,"doc-detail-429909-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-relapsedrefractory-and-mrd-ph-all-olverembatinibvenetoclax-bridging-enhances-allo-hsct-outcome","Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinibvenetoclax bridging enhances allo-HSCT outcome","","Olverembatinib-venetoclax was evaluated as a bridging regimen before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult Ph/BCR-ABL1+ acute lymphoblastic leukemia (ALL) with refractory/relapsed disease (n=2) or persistent MRD positivity (n=15). Seventeen patients were treated between February 2022 and January 2023; 4 harbored the T315I mutation. All patients achieved hematologic complete remission and 70.6% achieved complete molecular remission. With a median 856-day follow-up, 2-year overall survival and relapse-free survival were 88.2% and 79.4%. The regimen showed high molecular response and acceptable tolerability for MRD clearance prior to allo-HSCT.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-relapsedrefractory-and-mrd-ph-all-olverembatinibvenetoclax-bridging-enhances-allo-hsct-outcome/429909/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-relapsedrefractory-and-mrd-ph-all-olverembatinibvenetoclax-bridging-enhances-allo-hsct-outcome/429909.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient population was studied for the olverembatinib-venetoclax bridging regimen?","Question",{"text":112,"@type":113},"Adult Ph/BCR-ABL1+ ALL patients with refractory/relapsed disease (n=2) or persistent minimal residual disease (MRD) positivity (n=15) were included. Seventeen patients were enrolled from February 2022 to January 2023.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What remission outcomes were achieved after treatment?",{"text":117,"@type":113},"All 17 patients achieved hematologic complete remission. Complete molecular remission was achieved by 70.6% of patients.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the post-HSCT survival outcomes after a median follow-up?",{"text":121,"@type":113},"After a median follow-up of 856 days post-HSCT, the 2-year overall survival and relapse-free survival rates were 88.2% and 79.4%, respectively.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},429909,1790971780,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Annals of Hematology (2025) 104:6463–6466  \n[https://doi.org/10.1007/s00277-025-06708-0](https://doi.org/10.1007/s00277-025-06708-0)  \nCORRESPONDENCE  \nTargeting relapsed/refractory and MRD + Ph + ALL: olverembatinibvenetoclax bridging enhances allo-HSCT outcome  \nXiaoyu Zhang1,2 · Yanhong Zhao1,2 · Weihua Zhai1,2 · Qiaoling Ma1,2 · Yigeng Cao1,2 · Jialin Wei1,2 · Chen Liang1,2 · Xin Chen1,2 · Wenbin Cao1,2 · Donglin Yang1,2 · Aiming Pang1,2 · Yi He1,2 · Sizhou Feng1,2 · Mingzhe Han1,2 · Rongli Zhang1,2,3 · Erlie Jiang1,2,3  \nReceived: 12 June 2025 / Accepted: 22 October 2025 / Published online: 13 December 2025 © The Author(s) 2025  \nAbstract  \nOlverembatinib is a novel third-generation TKI available in mainland China. However, there are only a few published clinical reports. In this study, we aimed to investigate the efficacy and safety of an olverembatinib-venetoclax regimen before bridging to HSCT in adult Ph/BCR-ABL1 +ALL patients with refractory/relapsed disease (n= 2) or persistent minimal residual disease (MRD) (n= 15) . Seventeen Ph +ALL patients who were admitted to our center between February 2022 and January 2023 were enrolled. Four patients harbored a T315I mutation. In all, 100% achieved hematologic complete remission, and 70.6% achieved complete molecular remission. With a median follow-up of 856-day post-HSCT, the 2-year overall survival and relapsed free survival rates was 88.2 ± 7.8% and 79.4 ± 10.9%, respectively. The findings ofthis study suggest that in Ph +ALL patients with disease recurrence and persistent MRD positivity, olverembatinib-venetoclax regimen showed a high molecular response rate and was well-tolerated in MRD clearance bridged to allo-HSCT.  \nKeywords Ph +ALL · Olverembatinib · Allo-HSCT · Venetoclax · Complete molecular remission  \nTo Editor,  \nDespite significant progress in tyrosine kinase inhibitors (TKIs) and optimized allogeneic hematopoietic stem cell transplantation (allo-HSCT) protocols, the prognosis of refractory Philadelphia chromosome (Ph)/BCR-ABL1 + acute lymphoblastic leukemia (ALL) remains dismal, as post-transplant relapse compromises survival outcomes. Prior studies have reported the limited efficacy of the second-/third-generation TKIs monotherapy in this scenario  \n􀀍 Rongli Zhang [zhangrongli@ihcams.ac.cn](zhangrongli@ihcams.ac.cn)  \n􀀍 Erlie Jiang [jiangerlie@ihcams.ac.cn](jiangerlie@ihcams.ac.cn)  \n1 State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300060, China  \n2 Tianjin Institutes of Health Science, Tianjin 301600, China  \n3 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 288 Nanjing Road, Tianjin 300060, China  \n[1, 2] . This highlights the urgent need for novel strategies to attain meaningful remission depth prior to HSCT [3] . Asthe only approved third-generation TKI in mainland China, olverembatinib has demonstrated potent activity against T315I-mutated chronic myeloid leukemia (CML) resistant to prior therapies [4] . Meanwhile, emerging evidence highlights synergistic antileukemic activity between TKIs and Bcl-2 inhibitors [5, 6], with reports demonstrating improved response rates using a triplet combination of ponatinib, venetoclax, and dexamethasone in relapsed Ph + ALL [7, 8] . However, clinical studies on olverembatinib-venetoclaxin Ph + ALL are still limited.  \nThis single-center case series included 17 refractory/ relapsed (R/R) (n= 2) and minimal residual disease (MRD) persistent positive (n= 15) Ph +ALL patients who were treated with olverembatinib-related therapy between February 20, 2022, and January 31, 2023 at the Stem Cell Transplantation Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. This study was part of a lar","cbCaimC3kpjJGjHa","https://ap.wps.com/l/cbCaimC3kpjJGjHa","pdf",670720,"English","# Abstract\n# Introduction\n# Methods and regimen\n## Patient cohort and study design\n## Treatment and follow-up\n# Results and outcomes\n# Keywords","[{\"question\":\"What patient population was studied for the olverembatinib-venetoclax bridging regimen?\",\"answer\":\"Adult Ph/BCR-ABL1+ ALL patients with refractory/relapsed disease (n=2) or persistent minimal residual disease (MRD) positivity (n=15) were included. Seventeen patients were enrolled from February 2022 to January 2023.\"},{\"question\":\"What remission outcomes were achieved after treatment?\",\"answer\":\"All 17 patients achieved hematologic complete remission. Complete molecular remission was achieved by 70.6% of patients.\"},{\"question\":\"What were the post-HSCT survival outcomes after a median follow-up?\",\"answer\":\"After a median follow-up of 856 days post-HSCT, the 2-year overall survival and relapse-free survival rates were 88.2% and 79.4%, respectively.\"}]","Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinibvenetoclax bridging enhances allo-HSCT outcome | PDF",1790651475]